Specify a stock or a cryptocurrency in the search bar to get a summary
Silk Road Medical Inc
SILKSilk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure. The company was incorporated in 2007 and is headquartered in Sunnyvale, California. As of September 17, 2024, Silk Road Medical, Inc operates as a subsidiary of Boston Scientific Corporation. Address: 1213 Innsbruck Drive, Sunnyvale, CA, United States, 94089
Analytics
WallStreet Target Price
20.75 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures SILK
Dividend Analytics SILK
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History SILK
Stock Valuation SILK
Financials SILK
Results | 2019 | Dynamics |